Pharma News India Weekly: GLP-1 Patent War, Price Hikes & Supply Chain Chaos (March 9-14, 2026)
Pharma News India Weekly: GLP-1 Patent War, Price Hikes & Supply Chain Chaos (March 9-14, 2026)
Welcome to this week's comprehensive roundup of everything happening in the Indian pharmaceutical industry. From major legal victories to raw material price shocks, here's what you need to know.
Quick Highlights
Delhi HC allows Dr. Reddy's to export semaglutide, dealing setback to Novo Nordisk
API prices surge 20-106% due to Iran conflict; glycerin up 64%
45,000 containers stranded affecting $1.5 billion export cargo
India-Uzbekistan pharma corridor launched targeting $10 billion market
CDSCO bans surrogate ads for GLP-1 drugs
Kedaara to sell Universal NutriScience for ₹3,000 crore
⚖️ GLP-1 Patent War: Dr. Reddy's Wins Major Legal Victory
Date: March 9-10
The Delhi High Court delivered a landmark ruling allowing Dr. Reddy's Laboratories to manufacture and export semaglutide to countries where Novo Nordisk lacks patent protection.
What Happened:
A division bench dismissed Novo Nordisk's appeal against a December 2025 order, observing that the company's species patent appeared "susceptible to revocation on grounds of obviousness." The court noted that semaglutide would be obvious from teachings in Novo's earlier genus patent (expired 2024).
Why It Matters:
Novo's Indian patent expires March 20, after which over 50 branded generics are expected to enter the market. Generic versions are expected at one-third to one-fifth the innovator price (₹3,000-5,000 vs ₹10,000-16,000 monthly).
Market Impact:
The GLP-1 segment recorded 177% sales growth on a moving annual turnover basis to ₹1,446 crore in February 2026. Eli Lilly's Mounjaro retained top spot as India's best-selling drug for the fifth consecutive month with ₹117 crore in February sales.
Raw Material Crisis: Prices Through the Roof
The Iran conflict is hitting pharmaceutical supply chains hard. Here's the latest data on price increases (December 2025 to March 2026):
| Ingredient | Increase | Use |
|---|---|---|
| Thiocolchicide | ▲ 106% | Muscle relaxant |
| Glycerin | ▲ 64% | Solvent, excipient |
| Nimesulide | ▲ 53% | Pain relief |
| Deflazacort | ▲ 50% | Steroid |
| Clobetasol Propionate | ▲ 47% | Skin treatment |
| Paracetamol | ▲ 26% | Fever, pain |
| Diclofenac Sodium | ▲ 25-30% | Anti-inflammatory |
| Ciprofloxacin | ▲ 20-30% | Antibiotic |
Why Prices Are Rising:
Rupee depreciation against dollar
Petroleum-linked solvent costs (up 20-30% in one week)
Container shortages and vessel delays
Opportunistic pricing by some suppliers
Industry Response:
The Federation of Pharma Entrepreneurs has urged NPPA to allow price hikes under DPCO 2013 Para 19. Small manufacturers are most vulnerable, unable to absorb costs or pass them on due to price controls.
Supply Chain Disruption: 45,000 Containers Stranded
The Scale:
Approximately 40,000-45,000 Indian containers are stranded in international waters or at ports, affecting export cargo worth $1-1.5 billion. Around 80% are already in transit.
Cost Explosion:
Normal freight: $800-1,500 per container
War surcharges: $3,000-5,000 extra
Bunker fuel: Up 35% in one week
Shipping lines imposing $100-200 per TEU emergency charges
Medical Devices Hit:
Polypropylene prices surged ₹55/kg since December. Gas rationing by Adani Total Gas is impacting syringe and IV bag manufacturers, with supplies restricted to 40% of contracted quantity.
Government Relief:
The CBIC issued 15-day guidelines for returning cargo, permitting back-to-town facilities. The government is discussing Covid-era support including loan moratoriums for affected exporters.
Trade Expansion: India-Uzbekistan Pharma Corridor Launched
Date: March 9
India and Uzbekistan launched a structured pharmaceutical and nutraceutical trade corridor targeting the $7-10 billion Eurasian healthcare market.
What It Offers:
Regulatory harmonization
Investment facilitation
Market access for Indian manufacturers
Joint ventures and supply chain integration
FTA Update:
Commerce Minister Piyush Goyal highlighted that India's nine FTAs signed in four years have opened nearly two-thirds of global trade to Indian pharma. Negotiations are progressing well with GCC and Eurasia.
⚠️ Regulatory Crackdown: CDSCO Bans GLP-1 Surrogate Ads
Date: March 11
The Central Drugs Standard Control Organisation prohibited pharmaceutical companies from using "so-called awareness campaigns" to promote GLP-1 drugs.
The Context:
Eli Lilly and Novo Nordisk had launched aggressive multimedia campaigns featuring celebrities, framed as obesity awareness initiatives. The regulator viewed these as surrogate advertising for prescription-only drugs.
The Warning:
"Any promotional activity, including surrogate advertisements for prescription-only drugs shall be viewed seriously and may be treated as irrational or misleading marketing practice."
Also in Regulatory News:
NPPA launched an investigation into e-pharmacy dynamic pricing, targeting location-based algorithms and inflated base prices with discount claims.
Corporate News: Kedaara to Sell Universal NutriScience
Date: March 11
Kedaara Capital is preparing to sell Universal NutriScience for an expected ₹3,000 crore valuation. Investment bank Rothschild has been appointed to advise.
Company Snapshot:
Formed 2021: Acquired 16 nutraceutical brands from Sanofi India for ₹587 crore
Portfolio: Includes Seacod, top-selling cod liver oil brand
FY25 revenue: ₹230 crore (EBITDA ₹61 crore)
FY26 estimate: ₹350-400 crore (EBITDA ~₹100 crore)
Other Corporate News:
Aurobindo Pharma: Received VAI classification from USFDA for Andhra Pradesh unit
Cipla: Recalled 400+ cartons of Nilotinib capsules in US due to specification failure
Bharat Biotech: Celebrated 30 years, delivering 9 billion vaccine doses to 125+ countries
ACG: Became world's first pharma packaging company in WEF's Global Lighthouse Network
COVID Vaccine Compensation: SC Directs No-Fault Policy
Date: March 10
The Supreme Court directed the government to frame a no-fault compensation policy for individuals suffering serious adverse events following COVID-19 vaccination.
Scientific Breakthrough:
A NEJM study identified the molecular mechanism behind rare vaccine-induced blood clots (VITT). Antibodies from affected patients shared identical genetic features causing them to mistakenly target platelet factor 4 instead of viral protein VII.
International News Roundup (PharmaTimes)
Approvals:
MHRA approved deuruxolitinib for severe alopecia areata
NHS to offer fezolinetant for menopause hot flushes
Clinical Trials:
Aplagon dosed first patient in phase 2a peripheral arterial disease trial
UCB reported bimekizumab superiority in psoriatic arthritis
Kainova reported positive phase 1 data for DT-9081 in solid tumours
Frequently Asked Questions
What are the top pharmaceutical trends for 2026?
GLP-1 market expansion with 50+ generic entrants, geopolitical supply chain resilience, API price inflation, digital manufacturing transformation, FTA-driven export growth, and regulatory crackdown on surrogate advertising.
Where can I find all weekly pharma industry news?
For comprehensive weekly updates, visit GreenCrossIndia.com/blog.
How is the Iran war affecting Indian pharma?
API price hikes of 20-106%, solvent cost increases of 20-30%, freight cost doubling with $3,000-5,000 war surcharges, 45,000 stranded containers, and potential ₹2,500-5,000 crore export losses.
Will medicine prices increase in India?
Industry has urged NPPA to allow price hikes under DPCO 2013 Para 19 due to unprecedented input cost inflation. Prolonged conflict may force price revisions.
Key Data Points
| Metric | Value |
|---|---|
| GLP-1 sales (MAT Feb 2026) | ₹1,446 crore (▲177%) |
| Stranded containers | 40,000-45,000 |
| Export cargo affected | $1-1.5 billion |
| War surcharge per container | $3,000-5,000 |
| Glycerin price increase | 64% |
| Paracetamol API increase | 26% |
| API exports (FY25) | ₹41,500 crore |
| Universal NutriScience valuation | ₹3,000 crore |
Disclaimer and References
This article is prepared for informational and educational purposes only and summarizes pharmaceutical industry developments during 9–14 March 2026. The information has been compiled from publicly available reports and industry news sources including Economic Times, Business Line, Financial Express, Indian Express, Hindustan Times, Mint, Pharmarack market data, and international pharmaceutical news platforms. Readers are advised to verify official announcements from companies, regulators, and government authorities before making business, medical, or financial decisions.
Stay tuned for regular update. For daily news, bookmark GreenCrossIndia.com/blog
Comments
Post a Comment